
    
      This is a multi-center, single-arm, open-label study. The study plans to set up 3 dose
      groups, adopting a dose-escalating 3+3 design, and plan to recruit about 9-18 subjects with
      relapsed or refractory multiple myeloma.C-4-29 cells will be infused to the subject by
      intravenous infusion.
    
  